Fresenius SE & Co. (OTCMKTS:FSNUY) Short Interest Down 66.5% in March

Fresenius SE & Co. (OTCMKTS:FSNUY) was the recipient of a large drop in short interest in March. As of March 13th, there was short interest totaling 21,913 shares, a drop of 66.5% from the February 26th total of 65,445 shares. Based on an average trading volume of 220,277 shares, the short-interest ratio is currently 0.1 days. Currently, 0.0% of the company’s shares are sold short.

Fresenius SE & Co. Stock Down 0.7%

FSNUY traded down $0.09 during midday trading on Thursday, hitting $12.78. The company had a trading volume of 9,100 shares, compared to its average volume of 70,487. The stock’s 50 day moving average price is $14.28 and its 200 day moving average price is $14.40. Fresenius SE & Co. has a 52 week low of $9.78 and a 52 week high of $33.93. The company has a market capitalization of $28.79 billion, a price-to-earnings ratio of 20.29 and a beta of 0.75. The company has a quick ratio of 0.99, a current ratio of 1.26 and a debt-to-equity ratio of 0.49.

Fresenius SE & Co. (OTCMKTS:FSNUY) last released its quarterly earnings data on Wednesday, February 25th. The company reported $0.28 earnings per share (EPS) for the quarter. The company had revenue of $6.94 billion for the quarter. Fresenius SE & Co. had a net margin of 5.71% and a return on equity of 10.38%. On average, research analysts anticipate that Fresenius SE & Co. will post 0.79 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

FSNUY has been the topic of several research analyst reports. Citigroup restated a “buy” rating on shares of Fresenius SE & Co. in a research report on Tuesday, February 3rd. Morgan Stanley reiterated an “overweight” rating on shares of Fresenius SE & Co. in a report on Monday, December 15th. Three equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy”.

About Fresenius SE & Co.

Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments.